TY - JOUR
T1 - An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy
T2 - Proof of concept study
AU - Padovani, Laetitia
AU - Baret, Aurelie
AU - Ciccolini, Joseph
AU - Taieb, David
AU - Bardia, Farman
AU - Teissonnier, Laetitia
AU - Muracciole, Xavier
AU - Barlesi, Fabrice
AU - Barbolosi, Dominique
N1 - Publisher Copyright:
© 2016 The Authors.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Objective: Positron emission tomography with 18F fludeoxyglucose integrated with CT (18F-FDG PET/CT) is a recommended imaging procedure in the evaluation of non-small-cell lung cancers (NSCLCs). Radiochemotherapy (RCT) is a mainstay for treatment of locally advanced NSCLC, for which overall survival still remains poor. Early evaluation of treatment response may help in decisionmaking to complete radiotherapy (RT) or to switch to other treatment modalities. The present study aimed to evaluate the performance of new metabolic parameters based on a simplified kinetic analysis on a single time point (SKA-S)-derived mathematical method, as compared with standardized uptake value (SUV) measurement during RT. Methods: Four patients treated with RT or RCT for NSCLC were evaluated using 18F-FDG PET/CT during RT and after treatment completion. Whole-body 18F-FDG PET/CT was performed followed by four additional list-mode acquisitions centered over the target lesion. Response was evaluated at four times (i.e. PET1-PET4) by calculating standard SUV values and T80%, the time taken to reach 80% of 18F-FDG metabolized fraction using a SKA-S-derived mathematical method. Results: Data from SUV and T80% calculations were found to be controversial. T80% was found to be more predictive of clinical outcome. Conclusion: Although results from this pilot study should be further confirmed in a large prospective study, the data suggest that T80% is a promising metabolic biomarker for assessing early response to RT.
AB - Objective: Positron emission tomography with 18F fludeoxyglucose integrated with CT (18F-FDG PET/CT) is a recommended imaging procedure in the evaluation of non-small-cell lung cancers (NSCLCs). Radiochemotherapy (RCT) is a mainstay for treatment of locally advanced NSCLC, for which overall survival still remains poor. Early evaluation of treatment response may help in decisionmaking to complete radiotherapy (RT) or to switch to other treatment modalities. The present study aimed to evaluate the performance of new metabolic parameters based on a simplified kinetic analysis on a single time point (SKA-S)-derived mathematical method, as compared with standardized uptake value (SUV) measurement during RT. Methods: Four patients treated with RT or RCT for NSCLC were evaluated using 18F-FDG PET/CT during RT and after treatment completion. Whole-body 18F-FDG PET/CT was performed followed by four additional list-mode acquisitions centered over the target lesion. Response was evaluated at four times (i.e. PET1-PET4) by calculating standard SUV values and T80%, the time taken to reach 80% of 18F-FDG metabolized fraction using a SKA-S-derived mathematical method. Results: Data from SUV and T80% calculations were found to be controversial. T80% was found to be more predictive of clinical outcome. Conclusion: Although results from this pilot study should be further confirmed in a large prospective study, the data suggest that T80% is a promising metabolic biomarker for assessing early response to RT.
UR - http://www.scopus.com/inward/record.url?scp=84989943827&partnerID=8YFLogxK
U2 - 10.1259/bjr.20160061
DO - 10.1259/bjr.20160061
M3 - Article
C2 - 27043244
AN - SCOPUS:84989943827
SN - 0007-1285
VL - 89
JO - British Journal of Radiology
JF - British Journal of Radiology
IS - 1062
M1 - 20160061
ER -